Skip to main content

Advertisement

Log in

Imaging of primary breast cancer with 18F-fluorodeoxythymidine PET-CT reveals heterogeneity of proliferation throughout the tumour

  • Image of the month
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Tubiana M, Pejovic MH, Chavaudra N, Contesso G, Malaise EP. The long-term prognostic significance of the thymidine labelling index in breast cancer. Int J Cancer 1984;33:441–445

    Article  PubMed  CAS  Google Scholar 

  2. Chang J, Powles TJ, Allred DC, Ashley SE, Clark GM, Makris A, et al. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 1999;17:3058–3063

    PubMed  CAS  Google Scholar 

  3. Going JJ, Stanton PD, Cooke TG. Influences on measurement of cellular proliferation by histology and flow cytometry in mammary carcinomas labeled in vivo with bromodeoxyuridine. Am J Clin Pathol 1993;100:218–222

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mark Beresford.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Beresford, M., Sanghera, B., Wong, WL. et al. Imaging of primary breast cancer with 18F-fluorodeoxythymidine PET-CT reveals heterogeneity of proliferation throughout the tumour. Eur J Nucl Med Mol Imaging 33, 624 (2006). https://doi.org/10.1007/s00259-005-0037-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-005-0037-7

Keywords

Navigation